FK866 (APO866): Potent Non-Competitive NAMPT Inhibitor for Cancer Metabolism Research

Executive Summary: FK866 (APO866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), demonstrating nanomolar potency (Ki = 0.4 nM) and selectivity for NAD biosynthesis inhibition in cancer research (Ji et al. 2025). It effectively depletes intracellular NAD and ATP, triggering caspase-independent death in acute myeloid leukemia (AML) cells while sparing normal hematopoietic progenitors (APExBIO). FK866’s efficacy is validated in mouse xenograft models, where it inhibits tumor growth and improves survival. The compound is insoluble in water but highly soluble in DMSO and ethanol, facilitating experimental use. APExBIO supplies FK866 (APO866) as a validated, research-grade reagent.

Biological Rationale

Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in the NAD salvage pathway, critical for cellular energy metabolism and survival (Ji et al. 2025). Elevated NAD biosynthesis supports rapid proliferation in malignant hematologic cells, including AML. Inhibition of NAMPT disrupts NAD-dependent processes, selectively impairing cancer cell viability. Targeting NAMPT has emerged as a promising strategy for metabolic intervention in hematologic malignancies and other proliferative diseases (Targeting Cancer Metabolism with FK866). This article extends previous work by providing a current, benchmark-driven synthesis of FK866’s mechanism, selectivity, and translational relevance.

Mechanism of Action of FK866 (APO866)

FK866 (APO866) acts as a highly specific, non-competitive inhibitor of NAMPT, with a Ki of 0.4 nM measured in cell-free enzymatic assays (Ji et al. 2025). It blocks the conversion of nicotinamide to nicotinamide mononucleotide, leading to rapid NAD and subsequent ATP depletion. Loss of NAD disrupts glycolysis and oxidative phosphorylation, resulting in energy crisis and cell death, particularly in rapidly dividing hematologic cancer cells. Notably, FK866-induced cytotoxicity is caspase-independent and involves mitochondrial membrane depolarization and autophagy dependent on de novo protein synthesis (APExBIO). Normal human hematopoietic progenitors are less sensitive due to lower baseline NAD turnover and metabolic demand (Precise NAMPT Inhibition), clarifying the translational selectivity of FK866 over earlier NAD-depleting agents.

Evidence & Benchmarks

• FK866 inhibits purified human NAMPT with a Ki of 0.4 nM (cell-free, pH 7.4, 25°C) (Ji et al. 2025).
• IC50 values for FK866 in various cell lines range from 0.09 nM to 27.2 nM (in vitro, 48–72 h exposure, DMSO vehicle) (APExBIO).
• In AML cell models, FK866 induces caspase-independent cell death, confirmed by lack of PARP cleavage and mitochondrial depolarization (flow cytometry, 24 h post-treatment) (NAMPT Inhibition and the Future).
• FK866 spares normal hematopoietic progenitors at cytotoxic doses for AML cells (colony assays, IC50 >10-fold higher in normal cells) (Precise NAMPT Inhibition).
• In murine AML xenograft models, FK866 administration (5 mg/kg, i.p., daily for 10 days) inhibits tumor growth and improves survival versus vehicle controls (Ji et al. 2025).
• FK866 is insoluble in water (<0.1 mg/mL) but soluble in DMSO (≥19.6 mg/mL) and ethanol (≥49.6 mg/mL) at 25°C (APExBIO).

This article updates prior summaries by integrating new in vivo efficacy data and delineating the boundary between cancer-selective and normal cell effects, clarifying workflow advantages over broader cytotoxics (Scenario-Based Best Practices).

Applications, Limits & Misconceptions

FK866 (APO866) is a reference NAMPT inhibitor for:

• Studying NAD-dependent metabolic pathways in cancer biology and aging.
• Modeling selective cytotoxicity in acute myeloid leukemia (AML) and lymphoblastic lymphoma.
• Benchmarking NAD biosynthesis inhibitors in drug discovery pipelines.
• Investigating caspase-independent, mitochondria-mediated cell death.

For a strategic perspective on translational opportunities and limitations, see NAMPT Inhibition and the Future of Cancer Metabolism; this article extends that discussion with focused, evidence-based laboratory benchmarks and storage/solubility parameters.

Common Pitfalls or Misconceptions

• FK866 is not a competitive NAMPT inhibitor; it binds allosterically and does not compete with substrate for the active site (Ji et al. 2025).
• It is ineffective in cell types with compensatory NAD biosynthesis via alternative pathways (e.g., some non-hematologic tissues).
• FK866 does not induce classical caspase-dependent apoptosis; cell death is mediated through mitochondrial dysfunction and autophagy.
• Low water solubility precludes aqueous stock solutions; improper handling can result in precipitation or inconsistent dosing.
• FK866 is not suitable as a direct clinical agent; its current use is restricted to preclinical research settings (Precise NAMPT Inhibition).

Workflow Integration & Parameters

FK866 (APO866) is supplied by APExBIO (catalog A4381) as a solid compound. For experimental use, dissolve in DMSO (≥19.6 mg/mL) or ethanol (≥49.6 mg/mL) at room temperature. Store FK866 powder at –20°C; solutions are stable below –20°C for several months, but single-use aliquots are recommended to minimize freeze-thaw cycles (FK866 (APO866)). Use freshly prepared or properly stored stock solutions for reproducible results. For cellular assays, typical working concentrations range from 0.1 nM to 100 nM, depending on cell type and endpoint. Always include an appropriate vehicle control (DMSO or ethanol not exceeding 0.1–0.5% v/v). For in vivo xenograft work, validated dosing regimens include daily intraperitoneal injection of 5–10 mg/kg for 5–14 days (Ji et al. 2025).

For scenario-specific protocols and troubleshooting, see Scenario-Based Best Practices for FK866. This article provides updated, evidence-driven solution preparation and dosing recommendations.

Conclusion & Outlook

FK866 (APO866) is a validated, highly specific NAMPT inhibitor for cancer metabolism research, with unique selectivity for malignant hematopoietic cells through disruption of NAD biosynthesis. Its robust in vitro and in vivo efficacy benchmarks, coupled with well-defined workflow parameters, make it a gold-standard reagent in the field. Ongoing research continues to define its utility in broader contexts, including vascular aging and metabolic disease. For detailed product information and ordering, consult APExBIO’s FK866 (APO866) product page.